1
|
Adotama P, Grullon K, Ali S, Okoye GA. How We Do It: Our Method for Triamcinolone Injections of Acne Keloidalis Nuchae. Dermatol Surg 2023; 49:713-714. [PMID: 37040497 DOI: 10.1097/dss.0000000000003803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/13/2023]
Affiliation(s)
- Prince Adotama
- The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York
| | - Karina Grullon
- University of Chicago Pritzker School of Medicine, Chicago, Illinois
| | - Shaheir Ali
- Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
| | - Ginette A Okoye
- Howard University College of Medicine, 2041 Georgia Avenue Northwest, Towers Building, Suite 4300, Washington, District of Columbia 20060, USA
| |
Collapse
|
2
|
Al Hammadi A, Parmar NV, Aljefri K, Al Sharif O, Abdallah M, Ahmed HM, Ammoury A. Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs. Dermatol Ther (Heidelb) 2023:10.1007/s13555-023-00946-8. [PMID: 37338721 DOI: 10.1007/s13555-023-00946-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 05/24/2023] [Indexed: 06/21/2023] Open
Abstract
BACKGROUND Alopecia areata (AA) is an autoimmune disease characterized by non-scarring hair loss in adults and children. Clinical manifestations range from hair loss in small, well-circumscribed patches to total hair loss on the scalp or any other hair-bearing areas. Although the exact pathogenesis of AA is not fully understood, it is thought that loss of immune privilege caused by immunological dysregulation of the hair follicle is key. Genetic susceptibility also plays a role. Response to currently available treatments is widely variable, causing patient dissatisfaction and creating an unmet need. AA is frequently associated with multiple comorbidities, further affecting patient quality of life. AIMS AND FINDINGS AA causes a significant burden on dermatologists and healthcare systems in the Middle East and Africa. There is a lack of data registries, local consensus, and treatment guidelines in the region. Limited public awareness, availability of treatments, and patient support need to be addressed to improve disease management in the region. A literature review was conducted to identify relevant publications and highlight regional data on prevalence rates, diagnosis, quality of life, treatment modalities, and unmet needs for AA in the Middle East and Africa.
Collapse
Affiliation(s)
| | - Nisha V Parmar
- Department of Dermatology, Rashid Hospital, Dubai Health Authority, Dubai, UAE
| | | | - Osama Al Sharif
- King Fahad General Hospital, Medina, Kingdom of Saudi Arabia
| | | | | | - Alfred Ammoury
- Division of Dermatology, St George University Medical Center, Beirut, Lebanon
| |
Collapse
|
3
|
Rodríguez-Villa Lario A, Aguado-García Á, Andrés-Lencina JJ, Corredera C, García-Legaz Martínez M, Alonso de Celada RM, Subiabre-Ferrer D, Valenzuela-Oñate C, Ricart-Vayá JM, Gómez-Zubiaur A. Successful Response to a Combination of Intralesional Methotrexate and Fractional CO 2 Laser in Refractory Alopecia Areata: Case Report. Skin Appendage Disord 2022; 8:486-491. [PMID: 36407646 PMCID: PMC9672868 DOI: 10.1159/000524672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 04/20/2022] [Indexed: 11/03/2023] Open
Abstract
Introduction Refractory cases of alopecia areata (AA) may be considered a therapeutic challenge. Intralesional methotrexate (IL-MTX) has been used in other dermatological diseases rather than AA. Likewise, its topical use as an immunosuppressant drug may be of interest for the control of the lymphoid infiltrate in AA. On the other hand, the use of fractional ablative laser is supported in literature as an alternative or complementary treatment in AA, whilst the generation of columns of thermal damage may favour the migration of cells and cytokines that are beneficial. Case Presentation In this paper, we present 2 cases in which IL-MTX and ablative fractional CO2 laser were combined with excellent outcomes. Conclusion Previous research encompasses a total of 23 patients. Most patients presented with patchy AA. The doses administered ranged from 2.5 to 50 mg with an average frequency of 3 weeks. On average, most patients required a minimum of 3 sessions. One case employed 1% topical methotrexate ointment. Adverse local events were mild and transient. In conclusion, the concomitant application of these treatments has not been reported previously. Specific recommendations relating to the appropriate dosing of the drug, frequency of administration, and requirements for analytical control studies should be determined in further studies.
Collapse
Affiliation(s)
- Ana Rodríguez-Villa Lario
- Trichology Unit, Instituto Médico Ricart, Hospital Ruber Internacional, Grupo Quirónsalud, Madrid, Spain
- Department of Dermatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | - Ángel Aguado-García
- Trichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain
| | | | - Cristina Corredera
- Trichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain
| | | | | | | | | | - José María Ricart-Vayá
- Trichology Unit, Instituto Médico Ricart, Hospital Ruber Internacional, Grupo Quirónsalud, Madrid, Spain
- Trichology Unit, Instituto Médico Ricart, Hospital Quirónsalud Valencia, Valencia, Spain
| | - Alba Gómez-Zubiaur
- Trichology Unit, Instituto Médico Ricart, Hospital Ruber Internacional, Grupo Quirónsalud, Madrid, Spain
- Department of Dermatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| |
Collapse
|